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A b s t r A c t
The extensive use of nonsteroidal anti-inflammatory drugs (NSAIDs), both nonse-
lective and cyclooxygenase- 2–specific inhibitors, for the relief of acute and chronic 
musculoskeletal pain, in addition to gastrointestinal toxicity, confers serious cardio-
vascular toxicity that affects the overall risk/benefit ratio of this commonly employed 
therapy. A plethora of studies have provided convincing evidence for a high risk of 
adverse cardiovascular events associated with NSAIDs related to a number of risk 
factors, which are herein briefly reviewed and an algorithm is suggested for their safer 
use.
I N t r O D U c t I O N
Nonsteroidal anti-inflammatory drugs (NSAIDs) comprise nonselective and cy-
clooxygenase (COX)-2–specific inhibitors (Table 1), which are extensively used for 
the relief of acute and chronic pain associated with several medical conditions, like 
rheumatoid arthritis and osteoarthritis.1 Their use will most likely increase as the 
prevalence of osteoarthritis increases because of increased expected longevity of the 
population. However, in a plethora of clinical trials, serious adverse cardiovascular 
(CV) events have been reported with NSAID use,2-10 which constitutes an issue of public 
health importance that physicians should be aware of and guided by when prescribing 
these agents, especially in older individuals1 who also have an increased prevalence of 
CV disease, or generally in patients with preexisting medical conditions.11
Nonselective NSAIDs, like ibuprofen and naproxen, inhibiting both COX-1 and 
COX-2, have been available since the seventies, while the newer selective cyclooxyge-
nase-2 (COX-2) inhibitor drugs (the coxibs), like valdecoxib, rofecoxib and celecoxib, 
were introduced decades later (end of nineties).12
With regards to CV adverse effects of NSAIDs, the data are quite worrisome,2,4,7,10,13 
although some studies have produced mixed results.5,12,14,15 COX-2 inhibitors have 
been found to induce myocardial infarction (MI) and strokes, which have led to the 
withdrawal of rofecoxib and valdecoxib.3,6 The Alzheimer’s Disease Anti-inflammatory 
Prevention (ADAPT) trial was discontinued, in part because of an excess of CV events 
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noted with naproxen.16 On the other hand, pooled data from 13 
trials with 7718 participants showed that nonselective NSAIDs 
had no significant effect on CV events (odds ratio-OR 1.3).12 
No significant effect was seen for joint disease trials (OR 0.6) 
or Alzheimer disease trials (OR 1.6).12 There was no significant 
difference in results for naproxen and non-naproxen NSAIDs.
The cardiotoxicity associated with use of NSAIDs may be 
attributed to increase in blood pressure, inhibition of pros-
tacyclin synthesis, oxidative stress, and impaired endothelial 
function (Table 2). Both selective and nonselective NSAIDs 
inhibit COX-2-mediated prostaglandin E2 production, thus 
producing their analgesic and anti-inflammatory effects.12 
Inhibition of COX-1 by nonselective NSAIDs reduces the 
platelet aggregating factor thromboxane, which may have 
a cardioprotective effect as has been found with low-dose 
aspirin. Gastrointestinal (GI) toxicity is mitigated with use 
of COX-2 inhibitors compared with nonselective NSAIDs as 
COX-1-mediated cytoprotection is maintained. On the other 
hand, COX-2 inhibitors may have an adverse atherothrombotic 
profile, due to unopposed thromboxane synthesis and platelet 
aggregation. Furthermore, both nonselective and COX-2–
selective NSAIDs have been associated with an increased 
incidence of hospitalization for congestive heart failure and 
elevated blood pressure.10,17
N O N s E L E c t I V E  N O N s t E r O I D A L  
A N t I - I N F L A M M A t O r y  D r U G s
An increase in arterial blood pressure is seen within 
weeks of starting treatment with an NSAID.6 However, the 
magnitude of the hypertensive response varies from drug to 
drug within this class. For example, naproxen exerts minimal 
vasopressor effect, whereas blood pressure rises consistently 
during treatment with diclofenac. The impression is that the 
blood pressure rise secondary to NSAIDs is dose dependent, 
but there are few dose-response clinical trials reporting effects 
tAbLE 1. Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs)
Non-selective selective cOX-2 
Inhibitors
Salicylic Acid Derivatives • Celecoxib
• Aspirin • Etoricoxib
• Sulfasalazine • Lumiracoxib*
Par-aminophenol Derivatives • Valdecoxib**
• Acetaminophen (Paracetamol) • Rofecoxib**
Indole and Indene Acetic Acids • Parecoxib
• Indomethacin
• Sulindac
• Etodolac
Heteroaryl Acetic Acids
• Diclofenac
• Ketorolac
Arylpropionic Acids
• Ibuprofen
• Ketoprofen
• Naproxen
• Fenoprofen
• Fluriprofen
• Loxoprofen
Anthranilic Acids (Fenamates)
• Mefanamic acid
Enolic Acids
• Oxicams (Piroxicam/Meloxicam)
Sulfonanilides
• Nimesulide
*Not available due to serious hepatotoxicity; 
**Rofecoxib and valdecoxib have been withdrawn from the market.
N.B.: Celecoxib is currently the only COX-2 inhibitor available in the 
United States.17
tAbLE 2. Factors Conferring Cardiovascular Risk by 
NSAIDs
• Hypertensive effect or impaired response to antihypertensive 
therapy (retention of sodium, increased renal vascular 
constriction, microvascular dysfunction)
• Vascular disruption of COX-2 leading to depressed 
expression of endothelial nitric oxide synthase and 
consequent release and function of nitric oxide
• Impaired endothelial function 
• Interaction with aspirin (interference with the antiplatelet 
effects of aspirin)
• Prothrombotic effect of COX-2 inhibition, e.g. decreased 
production of the vasodilator prostacyclin (which also inhibits 
platelet activation) with concomitant unimpeded COX-1–
mediated production of platelet thromboxane A2
• Disruption of COX-2 dependence of hemodynamic stability 
and renal function
• Oxidative stress
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on blood pressure. Most studies of the hypertensive response 
to NSAIDs have focused on the role of the kidneys, because 
NSAIDs cause sodium retention and interfere with the action 
of antihypertensive drugs.6 In general, the available evidence 
suggests that the increase in CV risk of NSAIDs is commen-
surate with their hypertensive effect; however, interplay with 
several other factors may be equally important. 
An initial analysis of the REACH Registry was limited 
to 23,728 European patients (aged 67.2±9.8 years).8 A total 
of 20,588 (86.8%) had established atherothrombotic disease 
and 3140 (13.2%) had multiple risk factors only. At baseline, 
1573 patients (6.6%) received NSAIDs and 15,395 (64.9%) 
received aspirin. Among the 22,028 (92.8%) with complete 
2-year follow-up, 683 (3.2%) died from CV causes, while 
395 (1.9%) had MI, 665 (3.1%) stroke, 1651 (7.6%) cardiac 
major adverse CV events (MACE) (defined as the composite 
of CV death, MI or stroke) and 199 (1%) bleeding. NSAID 
use was independently associated with an increased risk of 
stroke (odds ratio-OR 1.635; p<0.001), and a trend towards 
an increased bleeding rate (OR 1.554; p=0.07). No associa-
tion was found between NSAID use and MI or MACE. The 
authors concluded that NSAID use in stable patients with 
established atherothrombotic disease or multiple risk factors 
is independently associated with a 64% increase in stroke rates 
at 2 years, whereas no significant effect was observed on CV 
death or non-fatal MI.
However, a more recent analysis from the same Registry, 
albeit of the entire registry population, comprising 44,095 
patients showed different results about the use of NSAID 
over 4 years of follow-up.10 NSAID use was associated with an 
increased hazard for MI (hazard ratio - HR 1.37; P = 0.002), 
stroke (HR 1.21; P = 0.048), heart failure hospitalizations (HR 
1.18; P = 0.013), and ischemic hospitalizations (HR 1.17; P = 
0.001) or combined end-points (CV death/MI/ stroke/ ischemic 
hospitalizations, HR 1.12, P = 0.003; CV death/MI/ stroke, HR 
1.16, P = 0.02). The authors concluded that among patients 
with stable atherothrombosis, NSAID use was associated 
with a higher risk of MI, stroke, and hospitalizations for both 
ischemia and heart failure.
As already mentioned, in another meta-analysis of 13 ran-
domized controlled trials assessing the effect of NSAIDs on 
CV events in trials of joint disease and Alzheimer’s disease, the 
authors concluded that NSAIDs had no significant effect on 
CV events or death in the joint disease trials, but an indication 
for risk was present in trials of Alzheimer’s disease.12 They also 
stated that there was no significant adverse or cardioprotective 
effect of naproxen.
c y c L O O X y G E N A s E - 2  N O N s t E r O I D A L 
A N t I - I N F L A M M A t O r y  D r U G s
The first observation of NSAID-associated CV risk came 
from the Vioxx Gastrointestinal Outcomes Research Study 
(VIGOR), which demonstrated a fivefold difference in the 
incidence of acute MI between patients treated with rofecoxib 
50 mg/day and naproxen 1000 mg/day,2 and was further cor-
roborated by a meta-analysis of clinical trials of celecoxib and 
rofecoxib.18 In addition, a nested case-control study sought to 
establish if risk was enhanced with rofecoxib at either high or 
standard doses compared with remote NSAID use or celecoxib 
use.3 A total of 1,394,764 people contributed 2,302,029 person 
years of observation time to the study cohort of NSAID us-
ers. Patients received various NSAIDs, including celecoxib 
(n=40,405), ibuprofen (991,261), naproxen (435,492), and 
rofecoxib (26,748). From this cohort, 8143 cases of serious 
coronary heart disease and 31,496 matched controls were iden-
tified. Among the cases, 2210 (27.1%) were fatal. Multivariate 
odds ratios versus celecoxib were: for rofecoxib (all doses), 
1.59 (p=0.015); for rofecoxib ≤25 mg/day, 1.47 (p=0·054); 
and for rofecoxib >25 mg/day, 3.58 (p=0.016). For naproxen 
versus remote NSAID use the odds ratio was 1.14 (p=0.05). 
The authors concluded that rofecoxib use increases the risk of 
serious coronary heart disease compared with celecoxib use, 
while naproxen use does not protect against serious coronary 
heart disease.
Another meta-analysis comprised 7,462 patients who 
received celecoxib (200 - 800 mg/day) for 1,268 patient-years 
who were compared with 4,057 patients treated with placebo 
for 585 patient-years, as well as 19,773 patients treated with 
similar dose of celecoxib for 5,651 patient-years who were com-
pared with 13,990 patients treated with nonselective NSAIDs 
(diclofenac, ibuprofen, naproxen, ketoprofen, and loxoprofen) 
for 4,386 patient-years.5 The incidence rates of the combined 
CV events were not significantly different between patients 
treated with celecoxib and placebo or between those treated 
with celecoxib and nonselective NSAIDs. Dose of celecoxib, 
the use of aspirin, or the presence of CV risk factors did not 
change these results. The authors concluded that these analy-
ses failed to demonstrate an increased CV risk with celecoxib 
relative to placebo and demonstrated a comparable rate of CV 
events with celecoxib treatment compared with nonselective 
NSAIDs. The authors also acknowledge a major limitation of 
their analysis, since all but one of the comparator trials did not 
exceed 1 year of patient follow-up.5
N O N s E L E c t I V E  A N D  s E L E c t I V E 
N s A I D s
A recent Danish study19 examined the risk of bleeding and 
CV events among 61,971 patients (mean age, 68) with prior 
MI taking antithrombotic drugs, who were also prescribed a 
NSAID. The number of deaths during a median follow-up of 
3.5 years was 18,105 (29.2%). A total of 5288 bleeding events 
(8.5%) and 18,568 CV events (30%) occurred. The crude 
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incidence rates of bleeding (events per 100 person-years) 
were 4.2 with concomitant NSAID treatment and 2.2 with-
out NSAID treatment, whereas the rates of CV events were 
11.2 and 8.3. Multivariate analysis found increased bleeding 
(hazard ratio-HR, 2.02) and CV risk (HR, 1.40) with NSAID 
treatment compared with no NSAID treatment. An increased 
risk of bleeding and CV events was evident with concomitant 
use of NSAIDs, regardless of antithrombotic treatment, types 
of NSAIDs, or duration of use. The authors concluded that 
among patients receiving antithrombotic therapy after MI, the 
use of NSAIDs was associated with increased risk of bleeding 
and excess thrombotic events, even after short-term treatment. 
In a post-hoc analysis from the INternational VErapamil 
Trandolapril STudy (INVEST),7 which enrolled patients with 
hypertension and coronary artery disease, at a mean follow-up 
of 2.7 years, the primary outcome (all-cause death, nonfatal 
MI, or nonfatal stroke) occurred at a rate of 4.4 events per 
100 patient-years in the chronic NSAID group (n=882), versus 
3.7 events per 100 patient-years in the non-chronic NSAID 
group (n=21,691; 14,408 never users and 7286 intermittent 
users) (HR 1.47; P=0.0003). This was due to an increase in 
CV mortality (HR 2.26; P<0.0001). The authors concluded 
that among hypertensive patients with coronary artery disease, 
chronic self-reported use of NSAIDs was associated with an 
increased risk of adverse events during long-term follow-up.
A recent Danish analysis20 of two cohort studies and two 
case-control studies explored additional (to MI, stroke, heart 
failure, and hypertension) NSAID-associated CV risks. The 
authors examined whether use of non-aspirin NSAIDs was as-
sociated with risk of MACE after coronary stent implantation, 
risk of venous thromboembolism, risk of atrial fibrillation, and 
30-day stroke mortality. They reported that use of non-aspirin 
NSAIDs was not associated with MACE following coronary 
stent implantation, but was associated with an increased risk 
of venous thromboembolism, atrial fibrillation, and 30-day 
mortality following ischemic stroke, especially when therapy 
with selective COX-2 inhibitors was initiated.
The MEDAL (Multinational Etoricoxib and Diclofenac 
Arthritis Long Term) program assessed the relative CV safety 
of two long-term anti-inflammatory treatments, etoricoxib and 
diclofenac, in 34,701 patients, 24,913 with osteoarthritis and 
9,787 with rheumatoid arthritis.21 Over an average treatment 
duration of 18 months, the rates of thrombotic CV events in 
patients on etoricoxib were similar to those in patients on 
diclofenac. Another analysis found a continuous linear dose 
relationship between specific diclofenac doses and the risk of 
a serious GI or CV event, thus giving credence to guidelines 
that recommend the use of NSAIDs at the lowest effective 
dose for the shortest duration.22-25
b A L A N c I N G  r I s K s  A N D  b E N E F I t s
NSAID selectivity is a continuous, not a dichotomous, 
variable, and rather a function of dose, while the risk varies 
from drug to drug.23 Diclofenac and celecoxib, for example, 
have almost equal selectivity. However, a COX-2 inhibitor 
given at high dose becomes a COX-1 inhibitor. Thus, high 
doses of COX-2 NSAIDs should be avoided. Most long-term 
data indicating increased CV risk are derived from trials with 
selective NSAIDs, but, as indicated above, an increase in 
overall CV risk is not confined to COX-2 NSAIDs and may 
be shared by a number of nonselective NSAIDs for which the 
data appear equally worrisome.6,25
N s A I D - A s p I r I N  I N t E r A c t I O N
Clinical trials and observational studies support the hy-
pothesis that nonselective NSAIDs interfere with the antiplate-
let effects of aspirin and block its cardioprotective effects. It 
has been shown that ibuprofen taken 2 hours before an aspirin 
dose may occupy the site during the entire time that aspirin is 
available to the platelet for permanent acetylation. The Food 
and Drug Administration (FDA) has issued a MedWatch 
that cautioned patients about the potential for ibuprofen to 
interfere with the CV protective effect of low-dose aspirin.6 
The FDA stated that since there are no data about the effect 
of other NSAIDs, until proven otherwise, patients should take 
aspirin 2 hours before taking an NSAID. In contrast, selective 
COX-2 inhibitors do not interfere with the actions of aspirin 
and preserve its ability to reduce the risk of MI and stroke in 
high-risk patients. On the other hand, studies to date suggest 
that aspirin lacks a favorable effect on CV risk in patients who 
take a selective COX-2 inhibitor. Thus, based on current data, 
a patient who takes aspirin for secondary prevention should 
not be prescribed a COX-2 inhibitor.
H y p E r t E N s I V E  A N D  c V  r I s K
The impact of NSAIDs in a non-hypertensive patient 
population is much less than in a hypertensive population, 
especially patients on angiotensin-converting enzyme (ACE) 
inhibitors, angiotensin receptor blockers, beta-blockers, and 
perhaps diuretics— but not calcium channel blockers. The 
available evidence suggests that selective and nonselective 
NSAIDs do not increase CV risk in the absence of a clinically 
meaningful increase in blood pressure.
Among hypertensive patients on drug therapy, NSAIDs 
have a much larger effect in elevating the blood pressure6 
or have harmful effects even when blood pressures appears 
controlled.7 The biggest changes are seen in patients on ACE 
inhibitors and beta blockers, because NSAIDs appear to in-
terfere with the action of those drugs. Blood pressure control 
in patients on calcium channel blockers appears to be unaf-
fected by NSAIDs.
The package-insert labeling on the CV risk of NSAIDs 
states, “NSAID may cause an increased risk of serious CV 
thrombotic events, MI, and stroke, which can be fatal. All 
NSAIDs may have a similar risk. This risk may increase with 
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duration of use. Patients with CV disease or CV risk factors 
may be at greater risk. NSAID is contraindicated for the treat-
ment of perioperative pain in the setting of coronary artery 
bypass graft surgery.”
A NSAID may promote thrombus formation. It is impor-
tant to differentiate between the effects of traditional NSAIDs 
and the COX-2s on thrombotic risk and hypertension. Both 
drug classes increase blood pressure and if untreated over the 
long term, this increase in blood pressure can contribute to 
the progression of CV disease, as would the hypertension of 
any etiology. However, the events that raised concern about 
the safety of these medications were acute thrombotic events, 
like MI and stroke. However, these events are not the conse-
quence of hypertension per se. This pathogenic mechanism is 
consistent with the effects of COX-2 selectivity and dose (i.e., 
more selective, higher doses), increasing baseline CV risk, and 
increased duration of treatment on the incidence of acute CV 
events. Furthermore, NSAIDs make platelets more reactive. 
The thrombotic event is a plaque rupture. Taking an NSAID, 
which inhibits prostacyclin, shifts platelet reactivity and in-
creases the likelihood of thrombus formation because the 
inhibitory effect of prostacyclin is decreased or lost. It should 
be noted that with an acute MI, the NSAID increases the risk. 
b A L A N c I N G  G I  A N D  c V  r I s K
If a patient has not responded or does not choose to 
undertake initial non-pharmacological approaches for the 
arthritic pain, it is recommended to start with a drug like 
acetaminophen, which, although not free of risk, may have 
less identified GI and CV risks. However, acetaminophen does 
have some hepatic and renal risk. In most guidelines, aceta-
minophen is a first-line drug.24,25 Aspirin is not really included 
in the guidelines, beyond low-dose aspirin, because the GI 
toxicity of aspirin beyond low doses is higher than that of any 
of the other NSAIDs. If an NSAID is required, the question 
arises as to which one should be prescribed. It is here that risk 
factors for GI tract bleeding become important and probably 
outweigh CV risk. These drugs are more alike in their CV risk 
than GI risk. In patients with higher GI risk, the risk/benefit 
ratio shifts in the direction of the COX-2 inhibitors (Figure 
1). For patients already taking low-dose aspirin, the risk/ben-
efit also shifts in favor of COX-2s, compared to nonselective 
NSAIDs, with their potential aspirin interaction. It should also 
be noted that Helicobactor pylori eradication reduces the risk 
of GI complications of NSAIDs.26
Also one should remember that risks with NSAIDs include 
hypertension and edema, but the biggest risk has always been 
FIGUrE 1. A suggested algorithm for use of NSAIDs. COX = cyclooxygenase; CV = cardiovascular; GI = gastrointestinal; Mod = 
moderate; NS = non-selective; NSAID = non-steroidal anti-inflammatory drug; PPI = proton pump inhibitor. 
* The American Heart Association25 suggests a stepped-care approach to pharmacological therapy for the management of musculo-
skeletal symptoms in patients with known CV disease or risk factors, focusing on agents with the lowest reported risk of CV events 
(acetaminophen, aspirin, tramadol, narcotic analgesics, nonacetylated salicylates) and then progressing toward other agents associated 
with increasing levels of CV risk, that is, non–COX-2–selective NSAIDs → NSAIDs with some COX-2 activity → COX-2–selective NSAIDs. 
** Ibuprofen is contraindicated when on aspirin.
N.B.: NSAIDs should be taken at the lowest effective dose for the shortest possible time to minimize both CV and GI risks.
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GI bleeding. The quoted rate is up to 50,000 deaths per year 
related to GI bleeding, with 10,000 preventable deaths! If one 
could reduce those in half with a strategy of using either a 
proton pump inhibitor (PPI) with a nonselective NSAID or a 
COX-2 inhibitor, then one would have considerably improved 
morbidity and mortality in this patient population. Indeed, 
rheumatologists worry more about complications of the GI 
tract than the heart.
Thus, GI bleeding is a major concern for patients taking 
NSAIDs. However, some clinicians are concerned that the 
GI safety advantage of COX-2-selective drugs is offset by 
an increase in CV risk. The GI safety advantage of 50 mg of 
rofecoxib compared to 500 mg bid naproxen in the VIGOR 
trial was offset by a similar increase in CV events. A similar 
increase in CV events was not seen in the CLASS (Celecoxib 
Long-Term Arthritis Safety Study) trial in patients using 800 
mg of celecoxib compared to usual doses of ibuprofen or di-
clofenac.27 Both of these trials were powered for GI events, and 
unfortunately, there are no published randomized controlled 
trials with COX-2 inhibitors powered for CV end points. In a 
large observational study of approximately 1.4 million patients 
in the California Kaiser-Permanente system, use of more than 
25 mg of rofecoxib was associated with an increased CV risk 
of about 300%, approximately the equivalent of the CV risk 
of cigarette smoking.3 However, a similar risk was not seen 
in this study with lower doses of rofecoxib and there was no 
observed increase in risk with celecoxib compared to nonusers 
of NSAIDs. A major discussion in rheumatology apparently 
is whether to prescribe a COX-2 inhibitor in patients with 
increased GI risk or a nonselective NSAID plus a PPI and 
whether patients will be compliant. In the absence of a tablet 
combining a PPI plus a NSAID, a COX-2 inhibitor has an ad-
vantage based on patient compliance with use of a single drug 
instead of two. The risk of GI bleeding on an NSAID plus a 
PPI regimen is about the same as a COX-2 inhibitor alone. In 
elderly patients with a prior history of GI bleeding who are on 
low dose aspirin, celecoxib plus a PPI is another alternative.
N s A I D  A G E N t  s E L E c t I O N
It is important that cardiologists, who are not among those 
physicians frequently prescribing NSAIDs, have a particular 
responsibility to be apprised of current information and data 
relevant to the CV risks of NSAIDs, especially when these 
agents are administered to patients receiving low-dose aspirin 
for cardioprotection.28 Moreover, every physician prescribing 
these agents should carefully weigh the benefits and risks of the 
use of NSAIDs from a CV and GI perspective by thoughtfully 
synthesizing the evidence for CV safety and prudently making 
decisions for individual patients (Fig. 1).17
According with a recent meta-analysis of data on the rela-
tive risk of CV events with individual NSAIDs listed on the 
Essential Medicines Lists (EMLs) of several countries, 3 drugs 
(rofecoxib, diclofenac, etoricoxib) had consistently highest CV 
risk compared with nonuse.9 Naproxen was associated with a 
low risk. Diclofenac was listed on 74 national EMLs, naproxen 
on 27. Rofecoxib use was not documented in any country, since 
its withdrawal. Diclofenac and etoricoxib accounted for one-
third of total NSAID usage. Diclofenac was by far the most 
commonly used NSAID. The authors concluded that listing 
of NSAIDs on national EMLs should take into account the 
associated CV risk, and since diclofenac has a risk very simi-
lar to rofecoxib, it should be withdrawn from the market and 
removed from EMLs.
The loss of prostaglandins has important homeostatic CV 
effects. When a selective or nonselective NSAID is given, a 
variety of prostaglandins are inhibited in the joint tissues, in 
the kidneys, and in blood vessels in a dose-dependent man-
ner. When high doses of certain drugs are given to susceptible 
patients, CV risk can increase.
Because risk has been established for many selective COX-
2 inhibitors but not for most nonselective NSAIDs, many clini-
cians prescribe a nonselective NSAID preferentially to patients 
who have 1 or more cardiac risk factors. However, there are 
no data suggesting that most nonselective NSAIDs carry less 
risk than most selective COX-2 inhibitors, regardless whether 
there is underlying hypertension or dyslipidemia. For patients 
with multiple underlying cardiac risk factors receiving low-dose 
aspirin, the evidence indicates that clinicians should prescribe a 
selective COX-2 inhibitor. In high-risk patients, it is critical to 
preserve the cardioprotective effects of aspirin, and this can be 
achieved only with a selective COX-2 inhibitor. Furthermore, 
there appears to be a dose effect of celecoxib in terms of CV 
risk, so at reasonably low doses, it may be relatively safe.
Thus, if an anti-inflammatory drug is needed for the treat-
ment of arthritis, the current evidence suggests that either 
naproxen or a low dose of celecoxib (200 mg daily) has no 
measurable CV risk. The 2 drugs that appear to carry the 
highest CV risk are rofecoxib (selective COX-2 inhibitor) 
and diclofenac (nonselective NSAID). The evidence with di-
clofenac is particularly worrisome. Diclofenac causes increased 
blood pressure and increased CV risk in both clinical trials and 
epidemiological studies.
Current recommendations also indicate that NSAIDs 
should be taken at the lowest effective dose for the shortest 
possible time to minimize both CV and GI risks.22,23 Caution 
should be particularly exercised in prescribing COX-1 and 2 
inhibitors for musculoskeletal disorders in patients who already 
suffer from GI or CV conditions. 
Most recently, the Pharmacovigilance Risk Assessment 
Committee (PRAC) of the European Medicines Agency 
(EMA) issued a warning of an increased risk of CV events in 
patients who take high doses of ibuprofen. The Committee 
states that there is a small increase in the risk of MI and stroke 
with ibuprofen when taken at doses of 2400 mg/day or higher 
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/
news_and_events/news/2015/04/news_detail_002306.
NONSTEROIDAL ANTI-INFLAMMATORy DRUGS
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jsp&mid=WC0b01ac058004d5c1). The risk, according 
to the committee, is similar to the risk observed with other 
NSAIDs, such as COX-2 inhibitors and diclofenac. However, 
the EMA had earlier stated that there was a consistent but 
small increase in the risk of CV side effects with diclofenac 
compared with other NSAIDs (http://www.ema.europa.eu/
ema/index.jsp?curl=pages/news_and_events/news/2013/06/
news_detail_001830.jsp&mid=WC0b01ac058001d126).
A very large prospective randomized NSAID study will 
be reporting long-awaited CV safety results in the next year.29 
The PRECISION (Prospective Randomized Evaluation of 
Celecoxib Integrated Safety vs Ibuprofen or Naproxen) trial 
has randomized approximately 24,000 patients with sympto-
matic rheumatoid arthritis or osteoarthritis and at high risk 
for or with established CV disease to 1 of 3 available NSAIDs 
(celecoxib, ibuprofen or naproxen).
From the above discussion, it becomes clear that we in dire 
need to develop new and effective NSAID formulations to 
minimize the safety and tolerability concerns associated with 
currently available NSAIDs, yet maintain efficacy in manage-
ment of inflammation and pain.30
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